US 6548055
Immunologic enhancement with intermittent interleukin-2 therapy
expired A61KA61K38/2013A61P
Quick answer
US patent 6548055 (Immunologic enhancement with intermittent interleukin-2 therapy) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Apr 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Apr 15 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K38/2013, A61P, A61P31/12, A61P37/04